GlassScriptPhysician profile
Jackson D Laizure
NPI 1437535846
$13,165.43
in general payments reported to CMS, 2019-2025
33 companies · $3,825 in 2025
The $3,825 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,906 · 2022: $2,224 · 2023: $2,131 · 2024: $3,080 · 2025: $3,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,926 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,926.00 |
| Education | $109.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,528.82 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,952.47 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,660.10 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,442.11 | 2021-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $1,046.13 | 2021-2025 | Epclusa |
| Lilly USA, LLC | $518.49 | 2023-2025 | Omvoh |
| Madrigal Pharmaceuticals | $468.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $453.60 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $450.95 | 2021-2025 | Linzess |
| Qol Medical, LLC | $357.68 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $337.57 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $264.93 | 2023-2025 | Ibsrela |
| Organon LLC | $247.92 | 2021-2024 | Hadlima, Renflexis |
| Ipsen Biopharmaceuticals, INC | $230.32 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $213.02 | 2024-2025 | Zenpep, Vowst |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $140.25 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $119.26 | 2021-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $98.28 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $86.34 | 2021-2023 | |
| Daiichi Sankyo INC. | $85.50 | 2021-2024 | Injectafer |
| Pfizer INC. | $72.80 | 2021-2025 | |
| Redhill Biopharma INC. | $64.55 | 2021-2022 | |
| Blueprint Medicines Corporation | $60.45 | 2025 | Ayvakit |
| Celltrion USA INC. | $47.76 | 2025 | Vegzelma |
| Baxter Healthcare | $44.50 | 2025 | Perclot |
| Amgen INC. | $39.97 | 2022-2023 | Avsola, Amjevita |
| Braintree Laboratories, INC. | $37.24 | 2021-2022 | |
| Sandoz INC. | $22.18 | 2024 | Hyrimoz |
| E.R. Squibb & Sons, L.L.C. | $17.67 | 2023 | Zeposia |
| Vivus LLC | $16.21 | 2024 | Qsymia |
| Boston Scientific Corporation | $15.68 | 2025 | Cre Pro |
| Merck Sharp & Dohme LLC | $13.21 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackson Laizure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.